KR20190051771A - Lactobacillus plantarum WiKim0062 having anti-obesity activity and composition comprising the same - Google Patents
Lactobacillus plantarum WiKim0062 having anti-obesity activity and composition comprising the same Download PDFInfo
- Publication number
- KR20190051771A KR20190051771A KR1020180088578A KR20180088578A KR20190051771A KR 20190051771 A KR20190051771 A KR 20190051771A KR 1020180088578 A KR1020180088578 A KR 1020180088578A KR 20180088578 A KR20180088578 A KR 20180088578A KR 20190051771 A KR20190051771 A KR 20190051771A
- Authority
- KR
- South Korea
- Prior art keywords
- wikim0062
- lactobacillus plantarum
- obesity
- present
- composition
- Prior art date
Links
- 240000006024 Lactobacillus plantarum Species 0.000 title claims abstract description 55
- 235000013965 Lactobacillus plantarum Nutrition 0.000 title claims abstract description 55
- 229940072205 lactobacillus plantarum Drugs 0.000 title claims abstract description 55
- 239000000203 mixture Substances 0.000 title abstract description 37
- 230000000694 effects Effects 0.000 title abstract description 16
- 230000003579 anti-obesity Effects 0.000 title abstract description 8
- 208000008589 Obesity Diseases 0.000 claims abstract description 24
- 235000020824 obesity Nutrition 0.000 claims abstract description 23
- 235000013305 food Nutrition 0.000 claims description 19
- 241000186660 Lactobacillus Species 0.000 claims description 11
- 229940039696 lactobacillus Drugs 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 10
- 201000010099 disease Diseases 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- 235000013361 beverage Nutrition 0.000 claims description 6
- 230000036541 health Effects 0.000 claims description 6
- 235000013376 functional food Nutrition 0.000 claims description 5
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 3
- 208000004930 Fatty Liver Diseases 0.000 claims description 2
- 206010019708 Hepatic steatosis Diseases 0.000 claims description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 claims description 2
- 208000001145 Metabolic Syndrome Diseases 0.000 claims description 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 claims description 2
- 208000015337 arteriosclerotic cardiovascular disease Diseases 0.000 claims description 2
- 235000015140 cultured milk Nutrition 0.000 claims description 2
- 208000010706 fatty liver disease Diseases 0.000 claims description 2
- 150000002632 lipids Chemical class 0.000 claims description 2
- 231100000240 steatosis hepatitis Toxicity 0.000 claims description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 2
- 241001465754 Metazoa Species 0.000 abstract description 15
- 239000006041 probiotic Substances 0.000 abstract description 9
- 235000018291 probiotics Nutrition 0.000 abstract description 9
- 235000021109 kimchi Nutrition 0.000 abstract description 4
- 230000002265 prevention Effects 0.000 abstract description 3
- 210000000936 intestine Anatomy 0.000 abstract 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 20
- 239000003925 fat Substances 0.000 description 16
- 239000003674 animal food additive Substances 0.000 description 15
- 241000894006 Bacteria Species 0.000 description 12
- 235000019197 fats Nutrition 0.000 description 11
- 230000000968 intestinal effect Effects 0.000 description 11
- 239000004310 lactic acid Substances 0.000 description 10
- 235000014655 lactic acid Nutrition 0.000 description 10
- 235000009200 high fat diet Nutrition 0.000 description 9
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 7
- 108010082126 Alanine transaminase Proteins 0.000 description 7
- 239000004480 active ingredient Substances 0.000 description 7
- 244000005700 microbiome Species 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 239000000796 flavoring agent Substances 0.000 description 6
- 235000013355 food flavoring agent Nutrition 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 239000008194 pharmaceutical composition Substances 0.000 description 6
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 6
- 238000009825 accumulation Methods 0.000 description 5
- 210000000577 adipose tissue Anatomy 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 235000000346 sugar Nutrition 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- 108020004465 16S ribosomal RNA Proteins 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 208000018522 Gastrointestinal disease Diseases 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 102000012335 Plasminogen Activator Inhibitor 1 Human genes 0.000 description 4
- 108010022233 Plasminogen Activator Inhibitor 1 Proteins 0.000 description 4
- 239000011230 binding agent Substances 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 235000005911 diet Nutrition 0.000 description 4
- 230000002708 enhancing effect Effects 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 239000000314 lubricant Substances 0.000 description 4
- 230000000813 microbial effect Effects 0.000 description 4
- 230000000529 probiotic effect Effects 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 241000286209 Phasianidae Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 210000000579 abdominal fat Anatomy 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 208000010643 digestive system disease Diseases 0.000 description 3
- 201000010063 epididymitis Diseases 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 208000018685 gastrointestinal system disease Diseases 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 235000021590 normal diet Nutrition 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 2
- 241000272517 Anseriformes Species 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 2
- 241001134659 Lactobacillus curvatus Species 0.000 description 2
- 241001468157 Lactobacillus johnsonii Species 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 240000008042 Zea mays Species 0.000 description 2
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 238000002869 basic local alignment search tool Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 235000005822 corn Nutrition 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 235000021107 fermented food Nutrition 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 210000005228 liver tissue Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000001630 malic acid Substances 0.000 description 2
- 235000011090 malic acid Nutrition 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 150000007523 nucleic acids Chemical group 0.000 description 2
- 239000001205 polyphosphate Substances 0.000 description 2
- 235000011176 polyphosphates Nutrition 0.000 description 2
- 244000144977 poultry Species 0.000 description 2
- 235000013594 poultry meat Nutrition 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- QJZYHAIUNVAGQP-UHFFFAOYSA-N 3-nitrobicyclo[2.2.1]hept-5-ene-2,3-dicarboxylic acid Chemical compound C1C2C=CC1C(C(=O)O)C2(C(O)=O)[N+]([O-])=O QJZYHAIUNVAGQP-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 235000007319 Avena orientalis Nutrition 0.000 description 1
- 244000075850 Avena orientalis Species 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- GUBGYTABKSRVRQ-DCSYEGIMSA-N Beta-Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 description 1
- 239000005996 Blood meal Substances 0.000 description 1
- 240000002791 Brassica napus Species 0.000 description 1
- 235000004977 Brassica sinapistrum Nutrition 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010012742 Diarrhoea infectious Diseases 0.000 description 1
- 108010082495 Dietary Plant Proteins Proteins 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 239000001263 FEMA 3042 Substances 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- 235000019733 Fish meal Nutrition 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 206010064147 Gastrointestinal inflammation Diseases 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 241000208818 Helianthus Species 0.000 description 1
- 235000003222 Helianthus annuus Nutrition 0.000 description 1
- 240000005979 Hordeum vulgare Species 0.000 description 1
- 235000007340 Hordeum vulgare Nutrition 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- IMQLKJBTEOYOSI-GPIVLXJGSA-N Inositol-hexakisphosphate Chemical compound OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O IMQLKJBTEOYOSI-GPIVLXJGSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
- IMQLKJBTEOYOSI-UHFFFAOYSA-N Phytic acid Natural products OP(O)(=O)OC1C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C1OP(O)(O)=O IMQLKJBTEOYOSI-UHFFFAOYSA-N 0.000 description 1
- 229920000388 Polyphosphate Polymers 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- 244000178231 Rosmarinus officinalis Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 241000277331 Salmonidae Species 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 239000005862 Whey Substances 0.000 description 1
- 102000007544 Whey Proteins Human genes 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 201000009840 acute diarrhea Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- 239000006053 animal diet Substances 0.000 description 1
- 235000021120 animal protein Nutrition 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 239000000022 bacteriostatic agent Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- 235000012216 bentonite Nutrition 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 229940036811 bone meal Drugs 0.000 description 1
- 239000002374 bone meal Substances 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 229940045110 chitosan Drugs 0.000 description 1
- 229950001002 cianidanol Drugs 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- CQAIPTBBCVQRMD-UHFFFAOYSA-L dipotassium;phosphono phosphate Chemical compound [K+].[K+].OP(O)(=O)OP([O-])([O-])=O CQAIPTBBCVQRMD-UHFFFAOYSA-L 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- -1 etc. Substances 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000004467 fishmeal Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 208000020694 gallbladder disease Diseases 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 235000020688 green tea extract Nutrition 0.000 description 1
- 229940094952 green tea extract Drugs 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000007366 host health Effects 0.000 description 1
- 239000004021 humic acid Substances 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940069445 licorice extract Drugs 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000013227 male C57BL/6J mice Methods 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 239000006872 mrs medium Substances 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000001272 neurogenic effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000467 phytic acid Substances 0.000 description 1
- 235000002949 phytic acid Nutrition 0.000 description 1
- 229940068041 phytic acid Drugs 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- OQZCJRJRGMMSGK-UHFFFAOYSA-M potassium metaphosphate Polymers [K+].[O-]P(=O)=O OQZCJRJRGMMSGK-UHFFFAOYSA-M 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 235000008476 powdered milk Nutrition 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 description 1
- 229940033123 tannic acid Drugs 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
- 229930195724 β-lactose Natural products 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/123—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
- A23C9/1234—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt characterised by using a Lactobacillus sp. other than Lactobacillus Bulgaricus, including Bificlobacterium sp.
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
- A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/332—Promoters of weight control and weight loss
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/169—Plantarum
-
- A23Y2220/67—
-
- C12R1/25—
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
- C12R2001/25—Lactobacillus plantarum
Abstract
Description
본 발명은 신규한 락토바실러스 플란타룸 WiKim0062 및 이를 포함하는 조성물에 관한 것이다.The present invention relates to a novel Lactobacillus plantarum WiKim0062 and a composition comprising the same.
풍요로운 사회로 발전함에 따라, 비만은 단순히 외모상의 문제뿐만 아니라 당뇨병, 고혈압, 심혈관계 질환, 뇌혈관계 질환, 관절염, 담낭 질환, 유방암, 대장암 등의 합병증을 유발할 수 있는 심각한 질병으로 보고됨에 따라 세계보건기구(WHO)는 비만을 치료해야 할 질병의 대상으로 명시하고 있다.With the development of a prosperous society, obesity has been reported as a serious disease that can cause complications such as diabetes, hypertension, cardiovascular disease, cerebrovascular disease, arthritis, gallbladder disease, breast cancer, and colon cancer, as well as an appearance problem. The Health Organization (WHO) specifies obesity as a target for diseases to be treated.
현재 시장을 주도하고 있는 대부분의 비만 억제제 또는 비만 치료제는 화학합성제품이 주를 이루고 있었으나, 적은 효과에 비해 다양한 부작용이 보고되고 있어, 천연물 유래의 비만억제 소재에 대한 관심이 증가하고 있는 추세이다. 이에, 효능의 지속성이 개선된 비만 치료제 및 부작용 없는 새로운 비만 치료제의 개발이 요구되고 있다. Most of the obesity inhibitors or obesity treatments that are currently leading the market mainly consist of chemically synthesized products, but various side effects have been reported compared to their small effect, and thus, interest in obesity inhibitory materials derived from natural products is increasing. Accordingly, there is a need for development of obesity treatments with improved persistence of efficacy and new treatments for obesity without side effects.
유산균은 장내 정상 균총의 유지, 장내 균총의 개선, 항당뇨 및 항지혈증 효과, 발암 억제, 대장암 억제, 숙주의 면역체계의 비특이적 활성 등의 효과를 나타낸다고 보고되고 있다. Lactobacillus has been reported to exhibit effects such as maintenance of normal intestinal flora, improvement of intestinal flora, antidiabetic and antilipidemia effects, suppression of carcinogenesis, inhibition of colon cancer, and nonspecific activity of the host's immune system.
현재까지 비만 예방 및 치료 관련으로 등록된 유산균 특허로는 락토바실러스 플란타룸(Lactobacillus plantarum) KY1032(특허문헌 1), 락토바실러스 커바터스(Lactobacillus curvatus) HY7601(특허문헌 2), 락토바실러스 플란타룸(Lactobacillus plantarum) DSR920(특허문헌 3), 락토바실러스 존소니(Lactobacillus johnsonii) HF1 108(특허문헌 4)이 개시되어 있다. 그러나 상업적으로 성공할 만큼 항비만 효과가 우수한 유산균 관련 기술은 출현하지 않고 있는 바, 항비만 효과가 우수한 새로운 균주의 스크리닝 및 이의 다양한 기능을 규명할 필요가 있다. Lactobacillus plantarum (Lactobacillus plantarum) KY1032 (Patent Document 1), Lactobacillus curvatus (Lactobacillus curvatus) HY7601 (Patent Document 2), Lactobacillus plantarum ( Lactobacillus plantarum ) DSR920 (Patent Document 3), Lactobacillus johnsonii (Lactobacillus johnsonii) HF1 108 (Patent Document 4) are disclosed. However, there is no emergence of technology related to lactic acid bacteria having excellent anti-obesity effect enough to be commercially successful, and it is necessary to screen new strains having excellent anti-obesity effect and to investigate various functions thereof.
본 발명은 항비만 활성이 우수한 락토바실러스 속 유산균을 제공하고자 한다.The present invention is to provide lactobacilli genus Lactobacillus having excellent anti-obesity activity.
이에, 본 발명자들은 전통발효식품으로부터 프로바이오틱스로서 우수한 효과를 나타내는 유산균 균주를 찾고자 노력한 결과, 신규한 락토바실러스 속 유산균 균주인 락토바실러스 플란타룸 WiKim0062(Lactobacillus plantarum WiKim0062)를 분리, 동정하여 본 발명을 완성하게 되었다.Accordingly, the present inventors tried to find a lactic acid bacteria strain that exhibits excellent effects as probiotics from traditional fermented foods, as a result of which the present invention was completed by separating and identifying Lactobacillus plantarum WiKim0062 (Lactobacillus plantarum WiKim0062), a novel Lactobacillus genus lactic acid strain. Was done.
본 발명에 따른 락토바실러스 플란타룸 WiKim0062(Lactobacillus plantarum WiKim0062)는 김치 유래의 락토바실러스 플란타룸 균주이다. 비록 본 발명에서의 락토바실러스 플란타룸 WiKim0062를 김치에서 분리, 동정하기는 했으나, 이의 입수 경로가 이에 한정되는 것은 아니다. Lactobacillus plantarum WiKim0062 (Lactobacillus plantarum WiKim0062) according to the present invention is a Lactobacillus plantarum strain derived from kimchi. Although the Lactobacillus plantarum WiKim0062 in the present invention was separated and identified from kimchi, the route of obtaining the Lactobacillus plantarum WiKim0062 is not limited thereto.
본 발명에의 실시예를 통해 전통발효식품으로부터 분리된 프로바이오틱스로서 우수한 효과를 나타내는 유산균 균주는 미생물의 동정 및 분류를 위한 16S rRNA 염기서열 분석 결과, SEQ ID NO: 1의 핵산서열을 갖는 것으로 나타났다.Lactobacillus strains exhibiting excellent effects as probiotics isolated from traditional fermented foods through the examples of the present invention were found to have a nucleic acid sequence of SEQ ID NO: 1 as a result of 16S rRNA sequence analysis for identification and classification of microorganisms.
따라서, SEQ ID NO: 1의 16S rRNA 염기서열을 갖는 본 발명의 미생물을 락토바실러스 플란타룸 WiKim0062(Lactobacillus plantarum WiKim0062)로 명명하였으며, 한국미생물보존센터에 2017년 07월 13일자로 기탁하였다(수탁번호 KCCM12081P).Therefore, the microorganism of the present invention having the 16S rRNA nucleotide sequence of SEQ ID NO: 1 was named Lactobacillus plantarum WiKim0062 (Lactobacillus plantarum WiKim0062), and was deposited with the Korea Microbial Conservation Center on July 13, 2017 (consignment). No. KCCM12081P).
본 발명의 락토바실러스 플란타룸 WiKim0062는 그람양성균이고 호기적 조건과 혐기적 조건에서 모두 성장이 가능한 통성 혐기성(facultative anaerobe)이며, 포자를 형성하지 않고 운동성이 없으며 세포는 간균의 형태를 취하고 있다. The Lactobacillus plantarum WiKim0062 of the present invention is a Gram-positive bacterium, is a facultative anaerobe that can grow in both aerobic and anaerobic conditions, does not form spores, has no motility, and the cells take the form of bacillus.
본 발명의 락토바실러스 플란타룸 WiKim0062는 프로바이오틱스로서, 유산균의 일반적인 정장 효과 및 면역 증강 효과를 갖는다. 락토바실러스 속의 유산균이 정장 효과 면역 증강 효과를 갖는다는 것은 잘 알려져 있는 사실이다.Lactobacillus plantarum WiKim0062 of the present invention is a probiotic, and has a general intestinal effect of lactic acid bacteria and an immune enhancing effect. It is a well-known fact that lactobacillus in the genus Lactobacillus has an intestinal effect and immune enhancing effect.
본 발명에 있어서, '프로바이오틱스(probiotics)'는 사람을 포함한 동물의 위장관 내에서 숙주의 장내 미생물 환경을 개선하여 숙주의 건강에 유익한 영향을 주는 살아있는 미생물'이라는 의미로 이해된다. 프로바이오틱스는 프로바이오틱 활성을 갖는 살아있는 미생물로 단일 또는 복합균주 형태로 사람이나 동물에 건조된 세포 형태나 발효산물 형태로 급여될 경우, 숙주의 장내 균총에 유익한 영향을 미칠 수 있다. In the present invention, "probiotics" are understood to mean "live microorganisms that have a beneficial effect on the health of the host by improving the intestinal microbial environment of the host in the gastrointestinal tract of animals including humans." Probiotics are living microorganisms having probiotic activity, and when fed in the form of dried cells or fermented products to humans or animals in the form of single or multiple strains, they can have a beneficial effect on the intestinal flora of the host.
하기 실시예에서는, 본 발명의 락토바실러스 플란타룸 WiKim0062가 체중 및 체지방에서 높은 축적 억제능을 보이고, 혈중 중성지방 및 간 기능과 관련된 GPT의 수치를 현저하게 저해시키는 것을 확인하였다. 또한, 상기 WiKim0062의 섭취에 따라 혈청 사이토카인인 PAI-1의 농도가 유의하게 감소하였음을 확인하였다. 따라서, 본 발명에 따른 락토바실러스 플란타룸 WiKim0062는 프로바이오틱스로서 사람 또는 동물의 정장, 비만 개선, 면역강화 등의 용도를 위해 다양하게 활용될 수 있다.In the following examples, it was confirmed that the Lactobacillus plantarum WiKim0062 of the present invention showed a high ability to inhibit accumulation in body weight and body fat, and significantly inhibited the levels of GPT related to blood triglyceride and liver function. In addition, it was confirmed that the concentration of the serum cytokine PAI-1 significantly decreased with the intake of WiKim0062. Therefore, the Lactobacillus plantarum WiKim0062 according to the present invention may be used in various ways for use in human or animal suits, obesity improvement, immunity enhancement, and the like as probiotics.
이에, 본 발명의 한 구체예에서는 락토바실러스 플란타룸 WiKim0062 또는 이의 배양물을 포함하는 프로바이오틱스 조성물을 제공한다. Accordingly, one embodiment of the present invention provides a probiotic composition comprising Lactobacillus plantarum WiKim0062 or a culture thereof.
본 발명에 따른 조성물에 포함되는 락토바실러스 플란타룸 WiKim0062는 생균체 또는 사균체로서 존재할 수 있으며, 또한 건조 또는 동결건조된 형태로 존재할 수도 있다. 다양한 조성물 내에 포함시키기 적합한 유산균의 형태 및 제제화 방법은 당업자에게 잘 알려져 있다. The Lactobacillus plantarum WiKim0062 included in the composition according to the present invention may exist as a live or dead cell, and may also exist in a dried or lyophilized form. Forms of lactic acid bacteria suitable for inclusion in various compositions and methods of formulation are well known to those skilled in the art.
한 구체예에서, 상기 조성물은 생균으로 존재하는 락토바실러스 플란타룸 WiKim0062 균주를 포함하는 경구 투여용 조성물일 수 있다.In one embodiment, the composition may be a composition for oral administration comprising the Lactobacillus plantarum WiKim0062 strain present as live bacteria.
본 발명의 한 구체예에서는 락토바실러스 플란타룸 WiKim0062 또는 이의 배양물을 포함하는 정장제 조성물을 제공한다. 본 발명에 따른 정장제 조성물은 사람을 포함한 동물의 위장 질환의 예방, 치료, 개선에 이용될 수 있으며, 바람직하게는 상기 동물은 소, 말, 돼지와 같은 가축을 포함한다. 상기 '위장 질환'으로는 위장 위해 세균감염 및 염증성 장 질환을 모두 포함하며, 예를 들어 병원성 미생물(대장균, 살모넬라, 클로스트리디움 등)에 의한 감염성 설사, 위장염증, 염증성 장 질환, 신경성 장염 증후군, 소장 미생물 과성장증, 장 급이성 설사 등을 포함하지만, 이에 한정되는 것은 아니다.One embodiment of the present invention provides an intestinal medicament composition comprising Lactobacillus plantarum WiKim0062 or a culture thereof. The intestinal composition according to the present invention can be used for the prevention, treatment, and improvement of gastrointestinal diseases in animals including humans, and preferably, the animals include livestock such as cattle, horses and pigs. The'gastrointestinal disease' includes both bacterial infection and inflammatory bowel disease for the stomach, for example, infectious diarrhea caused by pathogenic microorganisms (E. coli, Salmonella, Clostridium, etc.), gastrointestinal inflammation, inflammatory bowel disease, neurogenic enteritis syndrome. , Small intestine microbial hyperplasia, intestinal acute diarrhea, etc., but are not limited thereto.
본 발명에 따른 정장제 조성물은 경구로 투여하는 것이 바람직하다. 투여량은 위장 질환의 종류, 질환의 정도, 연령, 성별, 인종, 치료 또는 예방 목적 등에 따라 달라질 수 있으나, 일반적으로 성인을 기준으로 하루에 1천만 마리에서 1,000억마리를 투여할 수 있다.It is preferable to administer the intestinal composition according to the present invention orally. The dosage may vary depending on the type of gastrointestinal disease, the degree of the disease, age, sex, race, treatment or prevention purpose, etc., but generally, 10 million to 100 billion animals can be administered per day based on an adult.
본 발명은 락토바실러스 커바투스 WiKim0062 또는 이의 배양물을 포함하는 면역 증강용 조성물을 제공한다. 락토바실러스 속의 유산균이 정장 효과와 면역 증강 효과를 갖는다는 것은 잘 알려져 있는 사실이다.The present invention provides a composition for enhancing immunity comprising Lactobacillus curbatus WiKim0062 or a culture thereof. It is a well-known fact that lactobacillus in Lactobacillus has an intestinal effect and an immune enhancing effect.
본 발명은 또한 락토바실러스 플란타룸 WiKim0062 또는 이의 배양물을 포함하는 지방 축적 저해용 조성물을 제공한다. 이에, 본 발명은 락토바실러스 플란타룸 WiKim0062 또는 이의 배양물을 포함하는 비만 질환의 예방 및 개선용 조성물을 제공한다.The present invention also provides a composition for inhibiting fat accumulation comprising Lactobacillus plantarum WiKim0062 or a culture thereof. Accordingly, the present invention provides a composition for preventing and improving obesity diseases, including Lactobacillus plantarum WiKim0062 or a culture thereof.
본 발명에 따른 락토바실러스 플란타룸 WiKim0062는 이러한 유리한 작용으로 인해 의약, 건강기능식품, 식품, 사료, 사료 첨가제 또는 유산균 스타터에 포함될 수 있다. Lactobacillus plantarum WiKim0062 according to the present invention may be included in medicine, health functional food, food, feed, feed additive or lactic acid bacteria starter due to such an advantageous action.
한 구체예에서, 본 발명은 락토바실러스 플란타룸 WiKim0062 또는 이의 배양물을 유효성분으로 포함하는 지방 축적 저해용 식품 조성물을 제공한다. 본 발명에 있어서, 상기 식품 조성물은 비만 예방 및 개선용 식품일 수 있다. 상기 식품 조성물은 건강기능식품 또는 음료, 바 등의 형태를 포함할 수 있다.In one embodiment, the present invention provides a food composition for inhibiting fat accumulation comprising Lactobacillus plantarum WiKim0062 or a culture thereof as an active ingredient. In the present invention, the food composition may be a food for preventing and improving obesity. The food composition may include a health functional food, a beverage, a bar, or the like.
다른 구체예에서, 본 발명은 락토바실러스 플란타룸 WiKim0062 또는 이의 배양물을 유효성분으로 포함하는 비만 또는 비만 관련 질환의 예방 또는 치료용 약학 조성물을 제공한다. 상기 비만 관련 질환으로는 비만, 지방간, 제2형 당뇨, 고지혈증, 심혈관 질환, 동맥경화증 또는 지질 관련 대사증후군일 수 있으나, 이에 제한되는 것은 아니다.In another embodiment, the present invention provides a pharmaceutical composition for preventing or treating obesity or obesity-related diseases comprising Lactobacillus plantarum WiKim0062 or a culture thereof as an active ingredient. The obesity-related disease may be obesity, fatty liver, type 2 diabetes, hyperlipidemia, cardiovascular disease, arteriosclerosis, or lipid-related metabolic syndrome, but is not limited thereto.
본 발명의 조성물이 약제학적 조성물로 활용될 경우, 본 발명의 약제학적 조성물은 상기 유효성분 이외에 약제학적으로 적합하고 생리학적으로 허용되는 보조제를 사용하여 제조될 수 있으며, 상기 보조제로는 부형제, 붕해제, 감미제, 결합제, 피복제, 팽창제, 윤활제, 활택제 또는 향미제 등을 사용할 수 있다.When the composition of the present invention is used as a pharmaceutical composition, the pharmaceutical composition of the present invention may be prepared using a pharmaceutically suitable and physiologically acceptable adjuvant in addition to the active ingredient. Releases, sweeteners, binders, coatings, expanding agents, lubricants, lubricants or flavoring agents may be used.
상기 약제학적 조성물은 투여를 위해서 상기 기재한 유효성분 이외에 추가로 약제학적으로 허용가능한 담체를 1종 이상 포함하여 약제학적 조성물로 바람직하게 제제화할 수 있다.For administration, the pharmaceutical composition may contain one or more pharmaceutically acceptable carriers in addition to the above-described active ingredients, and may be preferably formulated into a pharmaceutical composition.
예를 들어, 정제 또는 캡슐제의 형태로의 제제화를 위해, 유효성분은 에탄올, 글리세롤, 물 등과 같은 경구, 무독성의 약제학적으로 허용가능한 불활성 담체와 결합될 수 있다. 또한, 원하거나 필요한 경우, 적합한 결합제, 윤활제, 붕해제 및 발색제 또한 혼합물로 포함될 수 있다. 적합한 결합제는 이에 제한되는 것은 아니나, 녹말, 젤라틴, 글루코스 또는 베타-락토오스와 같은 천연당, 옥수수감미제, 아카시아, 트래커캔스 또는 소듐올레이트와 같은 천연 및 합성검, 소듐 스테아레이트, 마그네슘 스테아레이트, 소듐 벤조에이트, 소듐아세테이트, 소듐 클로라이드등을 포함한다. 붕해제는 이에 제한되는 것은 아니나, 녹말, 메틸셀룰로스, 아가, 벤토니트, 잔탄검 등을 포함한다. 액상 용액으로 제제화되는 조성물에 있어서 허용가능한 약제학적 담체로는, 멸균 및 생체에 적합한 것으로서, 식염수, 멸균수, 링거액, 완충식염수, 알부민 주사 용액, 덱스트로즈 용액, 말토덱스트린 용액, 글리세롤, 에탄올 및 이들 성분 중 1 성분이상을 혼합하여 사용할 수 있으며, 필요에 따라 항산화제, 완충액, 정균제 등 다른 통상의 첨가제를 첨가할 수 있다. 또한 희석제, 분산제, 계면활성제, 결합제 및 윤활제를 부가적으로 첨가하여 수용액, 현탁액, 유탁액 등과 같은 주사용 제형, 환약, 캡슐, 과립 또는 정제로 제제화할 수 있다.For example, for formulation in the form of a tablet or capsule, the active ingredient may be combined with an oral, non-toxic pharmaceutically acceptable inert carrier such as ethanol, glycerol, water, and the like. In addition, if desired or necessary, suitable binders, lubricants, disintegrants and coloring agents may also be included in the mixture. Suitable binders are, but are not limited to, starch, gelatin, natural sugars such as glucose or beta-lactose, corn sweeteners, natural and synthetic gums such as acacia, trackcacanth or sodium oleate, sodium stearate, magnesium stearate, sodium benzo Eate, sodium acetate, sodium chloride, and the like. Disintegrants include, but are not limited to, starch, methylcellulose, agar, bentonite, xanthan gum, and the like. As acceptable pharmaceutical carriers for compositions formulated as liquid solutions, as sterilized and biocompatible, saline, sterile water, Ringer's solution, buffered saline, albumin injection solution, dextrose solution, maltodextrin solution, glycerol, ethanol, and One or more of these components may be mixed and used, and other conventional additives such as antioxidants, buffers, and bacteriostatic agents may be added as needed. In addition, diluents, dispersants, surfactants, binders, and lubricants may be additionally added to prepare injection formulations such as aqueous solutions, suspensions, emulsions, etc., pills, capsules, granules, or tablets.
나아가 해당 분야의 적절한 방법으로 Remington's Pharmaceutical Science, Mack Publishing Company, Easton PA에 개시되어 있는 방법을 이용하여 각 질환에 따라 또는 성분에 따라 바람직하게 제제화할 수 있다.Further, it may be preferably formulated according to each disease or ingredient using a method disclosed in Remington's Pharmaceutical Science, Mack Publishing Company, Easton PA as an appropriate method in the field.
또한, 본 발명은 락토바실러스 플란타룸 WiKim0062 또는 이의 배양물을 유효성분으로 포함하는 비만 개선 또는 지방 축적 저해용 식품일 수 있다. 상기 식품 조성물은 건강기능식품 또는 음료, 바 등의 형태를 포함할 수 있다. In addition, the present invention may be a food for improving obesity or inhibiting fat accumulation, including Lactobacillus plantarum WiKim0062 or a culture thereof as an active ingredient. The food composition may include a health functional food, a beverage, a bar, or the like.
본 발명에 있어서, 상기 균주를 유효성분으로 포함하는 식품 조성물은 발효유 등의 음료를 포함할 수 있다. 이에, 본 발명은 락토바실러스 플란타룸 WiKim0062 또는 이의 배양물로 이루어지는 발효용 유산균 스타터를 제공한다.In the present invention, the food composition comprising the strain as an active ingredient may include a beverage such as fermented milk. Thus, the present invention provides a lactic acid bacteria starter for fermentation consisting of Lactobacillus plantarum WiKim0062 or a culture thereof.
본 발명에 따른 식품 조성물은 상기 약제학적 조성물과 동일한 방식으로 제제화되어 기능성 식품으로 이용하거나, 각종 식품에 첨가할 수 있다. 본 발명의 조성물을 첨가할 수 있는 식품으로는 예를 들어, 음료류, 비타민복합제, 건강보조식품류 등이 있다.The food composition according to the present invention may be formulated in the same manner as the pharmaceutical composition and used as a functional food or added to various foods. Foods to which the composition of the present invention can be added include beverages, vitamin complexes, health supplements, and the like.
본 발명의 식품 조성물은 식품 제조시에 통상적으로 첨가되는 성분을 포함할 수 있으며, 예를 들어, 단백질, 탄수화물, 지방, 영양소, 조미제 및 향미제를 포함한다. 상술한 탄수화물의 예는 모노사카라이드, 예를 들어, 포도당, 과당 등; 디사카라이드, 예를 들어 말토스, 슈크로스, 올리고당 등; 및 폴리사카라이드, 예를 들어 덱스트린, 사이클로덱스트린 등과 같은 통상적인 당 및 자일리톨, 소르비톨, 에리트리톨 등의 당알콜이다. 향미제로서 천연 향미제 [타우마틴, 스테비아추출물 (예를 들어 레바우디오시드A, 글리시르히진 등]) 및 합성향미제(사카린, 아스파르탐 등)를 사용할 수 있다. 예컨대, 본 발명의 식품 조성물이 드링크제와 음료류로 제조되는 경우에는 구연산, 액상과당, 설탕, 포도당, 초산, 사과산, 과즙, 및 각종식물추출액 등을 추가로 포함시킬 수 있다.The food composition of the present invention may include ingredients that are commonly added during food production, and include, for example, proteins, carbohydrates, fats, nutrients, flavoring agents and flavoring agents. Examples of the aforementioned carbohydrates include monosaccharides such as glucose, fructose, and the like; Disaccharides such as maltose, sucrose, oligosaccharides, and the like; And polysaccharides, for example, common sugars such as dextrin and cyclodextrin, and sugar alcohols such as xylitol, sorbitol, and erythritol. As flavoring agents, natural flavoring agents [taumatin, stevia extract (eg, rebaudioside A, glycyrrhizin, etc.]) and synthetic flavoring agents (saccharin, aspartame, etc.) can be used. For example, when the food composition of the present invention is made of drinks and beverages, it may further include citric acid, liquid fructose, sugar, glucose, acetic acid, malic acid, fruit juice, and various plant extracts.
상기 본 발명에 따른 조성물은 사료첨가제 또는 사료로서 이용될 수 있다.The composition according to the present invention may be used as a feed additive or feed.
사료 첨가제로서 이용될 경우, 상기 조성물은 20 내지 90% 고농축액이거나 분말 또는 과립 형태로 제조될 수 있다. 상기 사료첨가제는 구연산, 후말산, 아디픽산, 젖산, 사과산등의 유기산이나 인산 나트륨, 인산 칼륨, 산성 피로인산염, 폴리인산염(중합인산염) 등의 인산염이나, 폴리페놀, 카테킨, 알파-토코페롤, 로즈마리 추출물, 비타민 C, 녹차 추출물, 감초 추출물, 키토산, 탄닌산, 피틴산 등의 천연 항산화제 중 어느 하나 또는 하나 이상을 추가로 포함할 수 있다. 사료로서 이용될 경우, 상기 조성물은 통상의 사료 형태로 제제화 될 수 있으며, 통상의 사료성분을 함께 포함할 수 있다.When used as a feed additive, the composition may be a high concentration of 20 to 90% or may be prepared in the form of a powder or granules. The feed additives are organic acids such as citric acid, humic acid, adipic acid, lactic acid, malic acid, or phosphates such as sodium phosphate, potassium phosphate, acid pyrophosphate, and polyphosphate (polyphosphate), polyphenol, catechin, alpha-tocopherol, rosemary. Any one or more of natural antioxidants such as extract, vitamin C, green tea extract, licorice extract, chitosan, tannic acid, and phytic acid may be further included. When used as a feed, the composition may be formulated in a conventional feed form, and may include a common feed ingredient.
상기 사료첨가제 및 사료는 곡물, 예를 들면 분쇄 또는 파쇄된 밀, 귀리, 보리, 옥수수 및 쌀; 식물성 단백질 사료, 예를 들면 평지, 콩, 및 해바라기를 주성분으로 하는 사료; 동물성 단백질 사료, 예를 들면 혈분, 육분, 골분 및 생선분; 당분 및 유제품, 예를 들면 각종 분유 및 유장 분말로 이루어지는 건조성분 등을 더 포함할 수 있으며, 이외에도 영양보충제, 소화 및 흡수향상제, 성장촉진제 등을 더 포함할 수 있다.The feed additives and feed include grains such as crushed or crushed wheat, oats, barley, corn and rice; Vegetable protein feeds, such as feeds based on rapeseed, soybeans, and sunflowers; Animal protein feeds such as blood meal, meat meal, bone meal and fish meal; It may further include a dry component composed of sugar and dairy products, for example, various powdered milk and whey powder, and may further include nutritional supplements, digestion and absorption enhancers, growth accelerators, and the like.
상기 사료첨가제는 동물에게 단독으로 투여하거나 식용 담체 중에서 다른 사료첨가제와 조합하여 투여할 수도 있다. 또한, 상기 사료첨가제는 탑드레싱으로서 또는 이들을 동물사료에 직접 혼합하거나 또는 사료와 별도의 경구제형으로 용이하게 동물에게 투여할 수 있다. 상기 사료첨가제를 동물사료와 별도로 투여할 경우, 당해 기술분야에 잘 알려진 바와 같이 약제학적으로 허용가능한 식용 담체와 조합하여, 즉시 방출 또는 서방성 제형으로 제조할 수 있다. 이러한 식용 담체는 고체 또는 액체, 예를 들어 옥수수전분, 락토오스, 수크로오스, 콩플레이크, 땅콩유, 올리브유, 참깨유 및 프로필렌글리콜일 수 있다. 고체 담체가 사용될 경우, 사료첨가제는 정제, 캡슐제, 산제, 트로키제 또는 함당정제 또는 미분산성 형태의 탑 드레싱일 수 있다. 액체 담체가 사용될 경우, 사료첨가제는 젤라틴 연질 캡슐제, 또는 시럽제나 현탁액, 에멀젼제, 또는 용액제의 제형일 수 있다. The feed additive may be administered to the animal alone or may be administered in combination with other feed additives in an edible carrier. In addition, the feed additives may be easily administered to animals as top dressings or directly mixed with animal feed or as an oral formulation separate from feed. When the feed additive is administered separately from animal feed, it can be prepared in an immediate release or sustained release formulation by combining it with a pharmaceutically acceptable edible carrier as well known in the art. Such edible carriers may be solid or liquid, for example corn starch, lactose, sucrose, soy flakes, peanut oil, olive oil, sesame oil and propylene glycol. When a solid carrier is used, the feed additive may be a tablet, a capsule, a powder, a troche, or a sugar-containing tablet, or a top dressing in a microdispersible form. When a liquid carrier is used, the feed additive may be a gelatin soft capsule, or a formulation of a syrup, suspension, emulsion, or solution.
또한, 상기 사료첨가제 및 사료는 보조제, 예를 들어 보존제, 안정화제, 습윤제 또는 유화제, 용액촉진제 등을 함유할 수 있다. 상기 사료첨가제는 침주, 분무 또는 혼합하여 동물의 사료에 첨가하여 이용될 수 있다.In addition, the feed additive and feed may contain adjuvants, such as preservatives, stabilizers, wetting or emulsifying agents, solution accelerators, and the like. The feed additive may be used by dipping, spraying, or mixing to add to animal feed.
본 발명의 사료 또는 사료첨가제는 포유류, 가금 및 어류를 포함하는 다수의 동물식이에 적용할 수 있다.The feed or feed additive of the present invention can be applied to a number of animal diets including mammals, poultry and fish.
상기 포유류로서 돼지, 소, 양, 염소, 실험용 설치동물, 및 실험용 설치동물뿐만 아니라, 애완동물(예: 개, 고양이) 등에게 사용할 수 있으며, 상기 가금류로서 닭, 칠면조, 오리, 거위, 꿩, 및 메추라기 등에도 사용할 수 있고, 상기 어류로서 송어 등에 이용될 수 있으나, 이에 한정되는 것은 아니다.As the mammal, pigs, cows, sheep, goats, experimental rodents, and experimental rodents, as well as pets (eg, dogs, cats), etc., can be used, and as the poultry, chickens, turkeys, ducks, geese, pheasants, And quail, and may be used for trout as the fish, but is not limited thereto.
한 구체예에서, 상기 사료 또는 사료첨가제는 애완동물의 비만 개선을 위해 사용될 수 있다. 상기 애완동물로는 개, 고양이, 쥐, 토끼 등이 있으나, 이에 제한되는 것은 아니다.In one embodiment, the feed or feed additive may be used to improve obesity in pets. The pets include, but are not limited to, dogs, cats, mice, and rabbits.
본 발명에 따른 사료는 동물의 체중 조절을 위해 사용될 수 있으며, 동물의 비만을 예방 또는 개선할 수 있다.The feed according to the present invention can be used to control the weight of animals, and can prevent or improve obesity in animals.
본 발명에 따른 조성물에 포함되는 락토바실러스 플란타룸 WiKim0062 균주의 양은 1회를 기준으로 약 106 내지 1012 cfu/g일 수 있으며, 예컨대 107 내지 1011 cfu/g, 108 내지 1010 cfu/g일 수 있다. 균주를 투여할 경우에는 생균 상태로 투여하는 것이 바람직하며, 섭취 전에 사멸시키거나 감쇄(attenuation) 상태로 투여할 수 있다. 또한, 배양 상등액 등을 사용하여 제조할 경우에는 열처리 과정을 통한 멸균화 과정을 추가적으로 거칠 수 있다. 최소의 효능을 가지는데 필요한 균주량 및 일일 섭취 정도는 섭취자의 신체 또는 건강상태에 따라 달라질 수 있으나, 일반적으로 약 106 내지 1012 cfu/g일 수 있으며, 예컨대 107 내지 1011 cfu/g, 108 내지 1010 cfu/g일 수 있다. The amount of the Lactobacillus plantarum WiKim0062 strain contained in the composition according to the present invention may be about 10 6 to 10 12 cfu/g, for example, 10 7 to 10 11 cfu/g, 10 8 to 10 10 It may be cfu/g. When administering the strain, it is preferable to administer it in a viable state, and it may be killed before ingestion or administered in an attenuation state. In addition, in the case of manufacturing using a culture supernatant or the like, a sterilization process through a heat treatment process may be additionally performed. The amount of strain and the degree of daily intake required to have the minimum efficacy may vary depending on the body or health condition of the ingestor, but may generally be about 10 6 to 10 12 cfu/g, such as 10 7 to 10 11 cfu/g , 10 8 to 10 10 cfu/g.
본 발명의 이점 및 특징, 그리고 그것들을 달성하는 방법은 상세하게 후술되어있는 실시예들을 참조하면 명확해질 것이다. 그러나 본 발명은 이하에서 개시되는 실시예들에 한정되는 것이 아니라 서로 다른 다양한 형태로 구현될 것이며, 단지 본 실시예들은 본 발명의 개시가 완전하도록 하고, 본 발명이 속하는 기술분야에서 통상의 지식을 가진 자에게 발명의 범주를 완전하게 알려주기 위해 제공되는 것이며, 본 발명은 청구항의 범주에 의해 정의될 뿐이다.Advantages and features of the present invention, and a method of achieving them will become apparent with reference to the embodiments described below in detail. However, the present invention is not limited to the embodiments disclosed below, but will be implemented in a variety of different forms, only the present embodiments are intended to complete the disclosure of the present invention, and the general knowledge in the technical field to which the present invention pertains. It is provided to completely inform the scope of the invention to the possessor, and the invention is only defined by the scope of the claims.
본 발명에 따른 락토바실러스 플란타룸 WiKim0062는 지방 축적 저해 등의 항비만 활성을 나타내므로, 프로바이오틱스로서 사람 또는 동물의 정장, 면역강화, 위장 질환 및 비만 개선 등의 용도를 위해 다양하게 활용될 수 있다. 나아가 발효용 스타터로서 유용하게 사용할 수 있다.Since the Lactobacillus plantarum WiKim0062 according to the present invention exhibits anti-obesity activity such as inhibition of fat accumulation, it can be variously used as a probiotic for use in human or animal intestinal tract, immunity enhancement, gastrointestinal disease and improvement of obesity. . Furthermore, it can be usefully used as a starter for fermentation.
도 1은 WiKim0062 섭취에 따른 마우스의 (A) 체중(Weight gain), (B) 체지방(Fat gain), 및 (C) 제지방(lean gain) 증가량을 나타낸 그래프이다.
도 2는 WiKim0062 섭취에 따른 마우스의 (A) 부고환 지방 (epididymal fat), (B) 복부 지방(abdominal fat), 및 (C) 간 조직(liver)의 감소 정도를 나타낸 그래프이다.
도 3은 WiKim0062 섭취에 따른 마우스의 혈중 (A) 중성지방(triglyceride; TG) 및 (B) GPT(glutamic pyruvic transaminase)의 감소 정도를 나타난 그래프이다.
도 4는 WiKim0062 섭취에 따른 마우스의 혈중 PAI-1(plasminogen activator inhibitor-1)의 감소 정도를 나타낸 그래프이다.1 is a graph showing (A) weight gain, (B) fat gain, and (C) lean gain increase in mice according to WiKim0062 intake.
2 is a graph showing the reduction in (A) epididymal fat, (B) abdominal fat, and (C) liver tissue (liver) of mice according to WiKim0062 intake.
3 is a graph showing the degree of reduction in blood (A) triglyceride (TG) and (B) glutamic pyruvic transaminase (GPT) in mice according to WiKim0062 intake.
4 is a graph showing the degree of reduction of plasma PAI-1 (plasminogen activator inhibitor-1) in the blood of mice according to WiKim0062 intake.
이하, 본 발명을 실시예를 통해 상세히 설명한다. 하기 실시예는 본 발명을 예시하는 것일 뿐 본 발명의 범위가 하기 실시예에 한정되는 것은 아니다.Hereinafter, the present invention will be described in detail through examples. The following examples are only illustrative of the present invention, and the scope of the present invention is not limited to the following examples.
[실시예][Example]
실시예 1: 락토바실러스 플란타룸 균주의 분리 및 동정Example 1: Isolation and identification of Lactobacillus plantarum strain
김치 추출물의 원액을 MRS 배지에 도말하여 얻은 균단일집락을 루프로 수거하여 MRS broth에 배양하였다. DNA 추출은 QIAamp DNA Mini Kit(QIAgen, Germany)를 사용하여 추출하였다. 추출된 DNA는 1% 아가로스 겔을 이용하여 확인하였으며, 16S rRNA gene을 증폭하기 위하여 추출된 genomic DNA를 주형으로 하여 PCR을 진행하였고, PCR 조건은 denaturation 95℃ 1분, annealing 45℃ 1 분, extension 72℃ 1 분 30초로 30 사이클을 수행하였다. 얻어진 PCR 산물은 마크로젠(Seoul, Korea)에 의뢰하여 서열을 분석하였다. 세균의 동정은 16SrRNA 서열을 National Center for Biotechnology Information(NCBI, www.ncbi.nlm.nih.gov)의 Basic Local Alignment Search Tool (BLAST) 검색엔진의 유사도 분석을 통해 수행하였다. A single colony of bacteria obtained by spreading the kimchi extract on MRS medium was collected with loops and cultured in MRS broth. DNA extraction was performed using the QIAamp DNA Mini Kit (QIAgen, Germany). The extracted DNA was confirmed using a 1% agarose gel, and PCR was performed using the extracted genomic DNA as a template to amplify the 16S rRNA gene, and PCR conditions were denaturation 95°C for 1 minute, annealing 45°C for 1 minute, 30 cycles were performed at an extension of 72° C. for 1 minute and 30 seconds. The obtained PCR product was sequenced by requesting Macrogen (Seoul, Korea). Bacterial identification was performed through the similarity analysis of the Basic Local Alignment Search Tool (BLAST) search engine of the National Center for Biotechnology Information (NCBI, www.ncbi.nlm.nih.gov) for 16SrRNA sequences.
본 발명의 실시예를 통해 분리된 균주는 미생물의 동정을 위한 16S rRNA 염기서열 분석 결과, SEQ ID NO: 1의 핵산서열을 갖는 것으로 나타났다. The strain isolated through the examples of the present invention was found to have the nucleic acid sequence of SEQ ID NO: 1 as a result of 16S rRNA sequencing analysis for the identification of microorganisms.
이에, 본 발명의 미생물을 락토바실러스 플란타룸 WiKim0062 (Lactobacillus plantarum WiKim0062)로 명명하였으며, 한국미생물보존센터에 2017년 07월 13일자로 기탁하였다 (수탁번호 KCCM12081P).Accordingly, the microorganism of the present invention was named Lactobacillus plantarum WiKim0062 (Lactobacillus plantarum WiKim0062), and was deposited with the Korea Microbial Conservation Center on July 13, 2017 (accession number KCCM12081P).
실시예 2: 락토바실러스 플란타룸 WiKim0062의 항비만 활성 확인Example 2: Confirmation of anti-obesity activity of Lactobacillus plantarum WiKim0062
4주령 수컷 C57BL/6J mice를 온도 20±2℃, 습도 50±5% 및 명암 주기(light-dark cycle) 12시간 단위인 조건의 사육실 환경하에서 chow diet(CD; Purina, Korea)로 1주간 적응시켰다. 실험동물은 정상 식이(D12450B, Research Diets, New Brunswick, NJ) 또는 총 칼로리의 45%가 지방인 고지방 식이(D12451, Research Diets, New Brunswick, NJ)를 섭취하도록 하였으며, 1주동안 식이에 적응시킨 후 실험을 수행하였다. 실험군은 정상 식이 섭취군(ND), 고지방 식이 섭취군(HFD), 고지방 식이와 함께 락토바실러스 플란타룸 WiKim0062(생균)를 1×109 CFU/200ul/day 농도로 매일 경구투여한 섭취군(HFD+WiKim0062)의 총 3개의 그룹으로 이루어져 있으며, 12주 동안 식이공급을 통해 비만을 유도하였다. 정상 식이 섭취군(ND)와 고지방 식이 섭취군(HFD)은 고지방 식이 및 WiKim0062 섭취군(HFD+WiKim0062)이 투여하는 WiKim0062 균주 대신 투여에 대한 스트레스 등을 배제하기 위해 이와 동일한 양의 인산완충식염수(phosphate buffered saline, PBS)을 매일 경구투여하였다. 실험 수행 12주 후, 락토바실러스 플란타룸 WiKim0062 투여에 따른 각 실험군의 체중, 체지방, 조직 무게, 혈중 중성지방, 간 기능 수치인 GPT 농도 및 혈청 사이토카인의 농도 변화를 아래와 같이 확인하였다.Four-week-old male C57BL/6J mice were adapted to a chow diet (CD; Purina, Korea) for 1 week in a breeding room environment with a temperature of 20±2℃, humidity of 50±5%, and a light-dark cycle of 12 hours. Made it. Experimental animals were allowed to consume a normal diet (D12450B, Research Diets, New Brunswick, NJ) or a high-fat diet (D12451, Research Diets, New Brunswick, NJ) in which 45% of total calories are fat. After the experiment was carried out. The experimental group was a normal diet intake group (ND), a high fat diet intake group (HFD), a high-fat diet and Lactobacillus plantarum WiKim0062 (live bacteria) daily orally administered at a concentration of 1×10 9 CFU/200 ul/day ( HFD+WiKim0062) consists of a total of 3 groups, and obesity was induced through dietary supply for 12 weeks. The same amount of phosphate-buffered saline in the normal diet intake group (ND) and the high fat diet intake group (HFD) in order to exclude the stress of administration instead of the WiKim0062 strain administered by the high-fat diet and WiKim0062 intake group (HFD+WiKim0062). phosphate buffered saline, PBS) was administered orally every day. After 12 weeks of conducting the experiment, changes in the body weight, body fat, tissue weight, blood triglyceride, GPT concentration, and serum cytokine concentration of each experimental group according to the administration of Lactobacillus plantarum WiKim0062 were confirmed as follows.
1) 체중 및 체지방 변화1) Changes in body weight and body fat
실험동물의 체중 및 체지방을 확인한 결과(도 1), 고지방 식이와 WiKim0062를 함께 섭취한 경우(HFD+WiKim0062), 고지방 식이 섭취 마우스(HFD)와 비교하여 체중 및 체지방 증가율이 각각 21%, 23%로 유의한 감소를 보였으나, 제지방(지방을 제외한 무게)에서는 큰 변화를 보이지 않았다.As a result of checking the body weight and body fat of the experimental animals (Fig. 1), when a high-fat diet and WiKim0062 were consumed together (HFD+WiKim0062), the weight and body fat increase rates were 21% and 23%, respectively, compared to the high-fat diet-ingested mice (HFD). However, there was no significant change in lean body (weight excluding fat).
2) 지방조직 무게 변화2) Fat tissue weight change
실험동물의 부고환 지방 (epididymal fat), 복부 지방(abdominal fat) 및 간(liver) 조직을 실험 종료 시에 적출하여, 생리 식염수에 세척하고 여과지에 수분을 제거한 후 중량을 측정하여 분석하였다.The epididymal fat, abdominal fat, and liver tissues of the experimental animals were excised at the end of the experiment, washed with physiological saline, removed moisture on a filter paper, and then weighed and analyzed.
그 결과(도 2), 고지방 식이와 WiKim0062을 함께 섭취한 HFD+WiKim0062 실험군의 경우, 고지방 식이 섭취 마우스(HFD)와 비교하여, 부고환 지방 및 복부 지방에서 각각 14%와 22% 감소하였으며, 간에서도 13%로 유의적인 감소를 나타내는 것을 확인할 수 있었다.As a result (FIG. 2), in the case of the HFD+WiKim0062 experimental group in which a high-fat diet and WiKim0062 were ingested together, compared with a high-fat diet-ingested mouse (HFD), the epididymal fat and abdominal fat decreased by 14% and 22%, respectively, and also in the liver. It was confirmed that a significant decrease was shown to 13%.
3) 혈중 중성지방 및 GPT 농도 변화3) Changes in blood triglyceride and GPT concentration
유산균의 섭취에 따른 혈중 중성지방 및 GPT 농도를 확인한 결과(도 3), 고지방 식이와 WiKim0062를 함께 섭취한 경우(HFD+WiKim0062), 고지방 식이 섭취 마우스(HFD)와 비교하여 29%로 유의적으로 감소하였으며, 특히 간 기능과 관련된 GPT 수치에서는 51% 감소한 것을 확인하였다.As a result of checking the blood triglyceride and GPT concentrations according to the intake of lactic acid bacteria (Fig. 3), when a high-fat diet and WiKim0062 were consumed together (HFD+WiKim0062), compared with a high-fat diet-ingested mouse (HFD), it was significantly (29%). It was confirmed that the GPT level related to liver function decreased by 51%.
4) 혈청 사이토카인 농도 변화4) Serum cytokine concentration change
유산균의 섭취에 따른 혈청 사이토카인의 농도를 확인한 결과(도 4), 고지방 식이와 WiKim0062를 함께 섭취한 경우(HFD+WiKim0062), 고지방 식이 섭취 마우스(HFD)와 비교하여 PAI-1의 농도가 23% 감소한 것을 확인하였다.As a result of checking the concentration of serum cytokines according to the intake of lactic acid bacteria (FIG. 4), when a high-fat diet and WiKim0062 were taken together (HFD+WiKim0062), the concentration of PAI-1 was 23 compared to that of a high-fat diet-ingested mouse (HFD). It was confirmed that the% decreased.
<110> Korea Food Research Institute <120> Lactobacillus plantarum WiKim0062 having anti-obesity activity and composition comprising the same <130> P17R10C1021 <160> 1 <170> KopatentIn 2.0 <210> 1 <211> 994 <212> RNA <213> Lactobacillus plantarum WiKim0062 <400> 1 gaagtacgat gtcggattta ttgggcgtaa gcgagcgcag gcggtttttt aagtctgatg 60 tgaaagcctt cggctcaacc gaagaagtgc atcggaaact gggaaacttg agtgcagaag 120 aggacagtgg aactccatgt gtagcggtga aatgcgtaga tatatggaag aacaccagtg 180 gcgaaggcgg ctgtctggtc tgtaactgac gctgaggctc gaaagtatgg gtagcaaaca 240 ggattagata ccctggtagt ccataccgta aacgatgaat gctaagtgtt ggagggtttc 300 cgcccttcag tgctgcagct aacgcattaa gcattccgcc tggggagtac ggccgcaagg 360 ctgaaactca aaggaattga cgggggcccg cacaagcggt ggagcatgtg gtttaattcg 420 aagctacgcg aagaacctta ccaggtcttg acatactatg caaatctaag agattagacg 480 ttcccttcgg ggacatggat acaggtggtg catggttgtc gtcagctcgt gtcgtgagat 540 gttgggttaa gtcccgcaac gagcgcaacc cttattatca gttgccagca ttaagttggg 600 cactctggtg agactgccgg tgacaaaccg gaggaaggtg gggatgacgt caaatcatca 660 tgccccttat gacctgggct acacacgtgc tacaatggat ggtacaacga gttgcgaact 720 cgcgagagta agctaatctc ttaaagccat tctcagttcg gattgtaggc tgcaactcgc 780 ctacatgaag tcggaatcgc tagtaatcgc ggatcagcat gccgcggtga atacgttccc 840 gggccttgta cacaccgccc gtcacaccat gaagagtttg taacacccaa agtcgggtgg 900 ggtaaccttt ttaggaacca gccgcctaag gtgggacaga tgattaaggt gaagtcgtaa 960 ggggttttcc cctaaaaaag ggtataaagt aagg 994 <110> Korea Food Research Institute <120> Lactobacillus plantarum WiKim0062 having anti-obesity activity and composition comprising the same <130> P17R10C1021 <160> 1 <170> KopatentIn 2.0 <210> 1 <211> 994 <212> RNA <213> Lactobacillus plantarum WiKim0062 <400> 1 gaagtacgat gtcggattta ttgggcgtaa gcgagcgcag gcggtttttt aagtctgatg 60 tgaaagcctt cggctcaacc gaagaagtgc atcggaaact gggaaacttg agtgcagaag 120 aggacagtgg aactccatgt gtagcggtga aatgcgtaga tatatggaag aacaccagtg 180 gcgaaggcgg ctgtctggtc tgtaactgac gctgaggctc gaaagtatgg gtagcaaaca 240 ggattagata ccctggtagt ccataccgta aacgatgaat gctaagtgtt ggagggtttc 300 cgcccttcag tgctgcagct aacgcattaa gcattccgcc tggggagtac ggccgcaagg 360 ctgaaactca aaggaattga cgggggcccg cacaagcggt ggagcatgtg gtttaattcg 420 aagctacgcg aagaacctta ccaggtcttg acatactatg caaatctaag agattagacg 480 ttcccttcgg ggacatggat acaggtggtg catggttgtc gtcagctcgt gtcgtgagat 540 gttgggttaa gtcccgcaac gagcgcaacc cttattatca gttgccagca ttaagttggg 600 cactctggtg agactgccgg tgacaaaccg gaggaaggtg gggatgacgt caaatcatca 660 tgccccttat gacctgggct acacacgtgc tacaatggat ggtacaacga gttgcgaact 720 cgcgagagta agctaatctc ttaaagccat tctcagttcg gattgtaggc tgcaactcgc 780 ctacatgaag tcggaatcgc tagtaatcgc ggatcagcat gccgcggtga atacgttccc 840 gggccttgta cacaccgccc gtcacaccat gaagagtttg taacacccaa agtcgggtgg 900 ggtaaccttt ttaggaacca gccgcctaag gtgggacaga tgattaaggt gaagtcgtaa 960 ggggttttcc cctaaaaaag ggtataaagt aagg 994
Claims (11)
상기 식품은 비만 예방 및 개선용 식품인, 식품 조성물.3. The method of claim 2,
Wherein the food is a food for preventing and improving obesity.
상기 식품은 건강기능식품인 조성물.3. The method of claim 2,
Wherein said food is a health functional food.
상기 식품은 음료, 바 또는 발효유인 조성물.3. The method of claim 2,
Wherein the food is a beverage, bar or fermented milk.
비만 관련 질환은 지방간, 제2형 당뇨, 고지혈증, 심혈관 질환, 동맥경화증 또는 지질 관련 대사증후군인 약학 조성물.The method according to claim 6,
Obesity-related diseases are fatty liver, type 2 diabetes, hyperlipidemia, cardiovascular disease, arteriosclerosis or lipid-related metabolic syndrome.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020180088578A KR20190051771A (en) | 2018-07-30 | 2018-07-30 | Lactobacillus plantarum WiKim0062 having anti-obesity activity and composition comprising the same |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020180088578A KR20190051771A (en) | 2018-07-30 | 2018-07-30 | Lactobacillus plantarum WiKim0062 having anti-obesity activity and composition comprising the same |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020170146841 Division | 2017-11-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20190051771A true KR20190051771A (en) | 2019-05-15 |
Family
ID=66579855
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020180088578A KR20190051771A (en) | 2018-07-30 | 2018-07-30 | Lactobacillus plantarum WiKim0062 having anti-obesity activity and composition comprising the same |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR20190051771A (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021137603A1 (en) * | 2019-12-31 | 2021-07-08 | 주식회사 지아이바이옴 | Lactobacillus plantarum strain, and composition for preventing or treating metabolic diseases containing same |
| WO2021215627A1 (en) * | 2020-04-21 | 2021-10-28 | (주)에이투젠 | Composition for preventing or treating lipid-related metabolic diseases, comprising lactobacillus plantarum atg-k2 or atg-k6 |
| KR20220032164A (en) * | 2020-09-07 | 2022-03-15 | 주식회사 휴먼바이오 | Pet snack composition comprising oriental melon and method for manufacturing the same |
| CN115087428A (en) * | 2020-12-30 | 2022-09-20 | 杰克斯博士株式会社 | Cosmetic composition comprising dead Lactobacillus plantarum or culture of Lactobacillus plantarum for preventing or improving skin aging |
| KR102506366B1 (en) * | 2022-08-16 | 2023-03-09 | (주)지에이치바이오 | Lactobacillus plantarum KU15120 strain or its use |
| KR102512998B1 (en) * | 2022-08-29 | 2023-03-23 | 콜마비앤에이치 주식회사 | New probiotics for reduction of body fat and use thereof |
| WO2023068434A1 (en) * | 2021-10-20 | 2023-04-27 | 주식회사 프로바이오닉 | Novel lactobacillus plantarum probio 93, and extract and composition thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100996577B1 (en) | 2009-04-01 | 2010-11-24 | 주식회사한국야쿠르트 | Lactobacillus curvatus HY7601 having inhibitory activity against blood cholestrol and obesity, and product containing thereof as an effective factor |
| KR101114498B1 (en) | 2008-07-21 | 2012-02-24 | 신현길 | Lactobacillus johnsonii HFI 108 having blood cholesterol level lowering and anti-obesity activity |
| KR101394348B1 (en) | 2011-10-28 | 2014-05-13 | 대상에프앤에프 주식회사 | Lactobacillus plantarum DSR920 having effect of treatment and prevention of metabolic or inflammatory diseases |
| KR101494279B1 (en) | 2010-10-01 | 2015-04-29 | 주식회사한국야쿠르트 | Lactobacillus plantarum KY1032 having inhibitory activity against adipocyte-specific gene expression and adipocyte differentiation, and product containing thereof as an effective factor |
-
2018
- 2018-07-30 KR KR1020180088578A patent/KR20190051771A/en active Application Filing
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101114498B1 (en) | 2008-07-21 | 2012-02-24 | 신현길 | Lactobacillus johnsonii HFI 108 having blood cholesterol level lowering and anti-obesity activity |
| KR100996577B1 (en) | 2009-04-01 | 2010-11-24 | 주식회사한국야쿠르트 | Lactobacillus curvatus HY7601 having inhibitory activity against blood cholestrol and obesity, and product containing thereof as an effective factor |
| KR101494279B1 (en) | 2010-10-01 | 2015-04-29 | 주식회사한국야쿠르트 | Lactobacillus plantarum KY1032 having inhibitory activity against adipocyte-specific gene expression and adipocyte differentiation, and product containing thereof as an effective factor |
| KR101394348B1 (en) | 2011-10-28 | 2014-05-13 | 대상에프앤에프 주식회사 | Lactobacillus plantarum DSR920 having effect of treatment and prevention of metabolic or inflammatory diseases |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021137603A1 (en) * | 2019-12-31 | 2021-07-08 | 주식회사 지아이바이옴 | Lactobacillus plantarum strain, and composition for preventing or treating metabolic diseases containing same |
| EP4086336A4 (en) * | 2019-12-31 | 2023-10-11 | Gi Biome | Lactobacillus plantarum strain, and composition for preventing or treating metabolic diseases containing same |
| WO2021215627A1 (en) * | 2020-04-21 | 2021-10-28 | (주)에이투젠 | Composition for preventing or treating lipid-related metabolic diseases, comprising lactobacillus plantarum atg-k2 or atg-k6 |
| KR20220032164A (en) * | 2020-09-07 | 2022-03-15 | 주식회사 휴먼바이오 | Pet snack composition comprising oriental melon and method for manufacturing the same |
| CN115087428A (en) * | 2020-12-30 | 2022-09-20 | 杰克斯博士株式会社 | Cosmetic composition comprising dead Lactobacillus plantarum or culture of Lactobacillus plantarum for preventing or improving skin aging |
| WO2023068434A1 (en) * | 2021-10-20 | 2023-04-27 | 주식회사 프로바이오닉 | Novel lactobacillus plantarum probio 93, and extract and composition thereof |
| KR102506366B1 (en) * | 2022-08-16 | 2023-03-09 | (주)지에이치바이오 | Lactobacillus plantarum KU15120 strain or its use |
| WO2024038980A1 (en) * | 2022-08-16 | 2024-02-22 | 주식회사 지에이치바이오 | Lactobacillus plantarum ku15120 strain or use thereof |
| KR102512998B1 (en) * | 2022-08-29 | 2023-03-23 | 콜마비앤에이치 주식회사 | New probiotics for reduction of body fat and use thereof |
| WO2024048934A1 (en) * | 2022-08-29 | 2024-03-07 | 콜마비앤에이치 주식회사 | Novel lactic acid lactiplantibacillus plantarum sko-001 bacterium for reducing body fat, and uses thereofhh |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN113498433B (en) | Composition for preventing, improving or treating obesity or fatty liver disease comprising leuconostoc citrate WiKim0104 | |
| KR20190051771A (en) | Lactobacillus plantarum WiKim0062 having anti-obesity activity and composition comprising the same | |
| KR102070143B1 (en) | Lactobacillus plantarum WiKim0060 having skin whitening and skin moisturizing activities and composition for comprising the same | |
| KR102123505B1 (en) | Lactobacillus sakei WIKIM0109 having anti-arthritis activity and composition for comprising the same | |
| JP7266110B2 (en) | Composition for prevention, improvement or treatment of obesity or fatty liver disease containing Weissella hellenica WIKIM0103 | |
| KR101838281B1 (en) | Lactobacillus curvatus WIKIM53 having anti-allergic disease activity and composition for comprising the same | |
| KR101995328B1 (en) | Lactobacillus fermentum WiKim0102 having anti-cancer activity and composition for comprising the same | |
| KR101834383B1 (en) | Weissella cibaria WIKIM28 having anti-obesity activity and composition for comprising the same | |
| KR101757785B1 (en) | Leuconostoc lactis WIKIM48 having high productivity of 2-hydroxyisocaproic acid and composition for comprising the same | |
| KR102313770B1 (en) | LACTOBACILLUS PLANTARUM WiKim0127 STRAIN DERIVED FROM JEJU PICKLED CABBAGE FOOD AND METHOD FOR PREPARING COMPOSITION USING SAME | |
| KR20190051772A (en) | Lactobacillus plantarum WiKim0061 having anti-obesity activity and composition comprising the same | |
| KR20160007964A (en) | Lactobacillus plantarum WIKIM18 and composition for comprising the same | |
| JP2019182763A (en) | Composition, and food and feed containing the same | |
| KR101838280B1 (en) | Leuconostoc citreum WIKIM56 having anti-arthritis activity and composition for comprising the same | |
| KR101834379B1 (en) | Weissella confusa WIKIM51 having anti-obesity activity and composition for comprising the same | |
| KR102313769B1 (en) | Lactobacillus plantarum wikim0126 strain derived from jeju pickled brussels sprout food and method for preparing composition using same | |
| KR102463809B1 (en) | Lactobacillus paracasei wikim0110 having antibacterial activity against clostridioides difficile and composition comprising the same | |
| KR102065180B1 (en) | Lactobacillus sp. WiKim0092 having antibacterial activity against Clostridioides difficile and composition comprising the same | |
| KR102065181B1 (en) | Lactobacillus sp. WiKim0093 having antibacterial activity against Clostridioides difficile and composition comprising the same | |
| KR20160039097A (en) | Pediococcus pentosaceus w i k i m20 and composition comprising the same | |
| KR101895564B1 (en) | Composition comprising Lactobacillus curvatus WIKIM55 having anti-obesity activity | |
| RU2816754C2 (en) | COMPOSITION FOR PREVENTING, IMPROVING OR TREATING OBESITY OR FATTY LIVER DISEASE CONTAINING LEUCONOSTOC CITREUM WiKim0104 | |
| KR102457366B1 (en) | Lactobacillus plantarum wikim0127 strain derived from jeju pickled cabbage food and method for preparing composition using same | |
| KR102546973B1 (en) | Composition for enhancing immunity comprising Bacillus velenzensis Kh2-2 | |
| KR102457367B1 (en) | Lactobacillus plantarum wikim0126 strain derived from jeju pickled brussels sprout food and method for preparing composition using same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A107 | Divisional application of patent |